Olema Pharmaceuticals (OLMA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.58, -4.22% vs the prior close of $6.87.
- Volume 1.08M shares, 0.9x its 50-day average.
- New SEC filings: SCHEDULE 13D/A (Oct 16, 2026), 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
OLMA slides 4.2% to $6.58, a 52-week low. Closed at $6.58, -4.22% vs the prior close of $6.87. Day range $6.48–$6.83, opened at $6.83.
OLMA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — OLMA slides 4.2% to $6.58, a 52-week low
- Closed at $6.58, -4.22% vs the prior close of $6.87. Day range $6.48–$6.83, opened at $6.83.
- Volume was 1.08M shares, 0.9x its 50-day average of 1.15M.
- Price is -31.6% vs its 50-day average ($9.62) and -56.2% vs its 200-day average ($15.01).
- 52-week range $6.48–$36.26; today's close sits at 0% of that range, 81.9% below the 52-week high.
Oct 15, 2026 — OLMA rises 1.0% to $6.87
- Closed at $6.87, +1.03% vs the prior close of $6.80. Day range $6.70–$6.95, opened at $6.84.
- Volume was 1.09M shares, 1.0x its 50-day average of 1.14M.
- Price is -29.4% vs its 50-day average ($9.73) and -54.5% vs its 200-day average ($15.10).
- 52-week range $6.61–$36.26; today's close sits at 1% of that range, 81.1% below the 52-week high.
- SEC filings that day: 8-K.
Oct 14, 2026 — OLMA slides 3.1% to $6.80, a 52-week low, 5 down days in a row
- Closed at $6.80, -3.13% vs the prior close of $7.02. Day range $6.61–$7.15, opened at $6.92.
- Volume was 1.85M shares, 1.6x its 50-day average of 1.13M.
- Price is -30.8% vs its 50-day average ($9.82) and -55.2% vs its 200-day average ($15.19).
- 52-week range $6.61–$36.26; today's close sits at 1% of that range, 81.2% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — OLMA slides 4.6% to $7.02, a 52-week low on 1.8x normal volume
- Closed at $7.02, -4.62% vs the prior close of $7.36. Day range $6.99–$7.36, opened at $7.30.
- Volume was 2.01M shares, 1.8x its 50-day average of 1.10M — unusually heavy trading.
- Price is -29.2% vs its 50-day average ($9.92) and -54.1% vs its 200-day average ($15.29).
- 52-week range $6.65–$36.26; today's close sits at 1% of that range, 80.6% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — OLMA slides 5.9% to $7.36, a 52-week low, 3 down days in a row
- Closed at $7.36, -5.88% vs the prior close of $7.82. Day range $7.33–$7.77, opened at $7.77.
- Volume was 1.02M shares, 0.9x its 50-day average of 1.10M.
- Price is -26.5% vs its 50-day average ($10.01) and -52.2% vs its 200-day average ($15.39).
- 52-week range $6.65–$36.26; today's close sits at 2% of that range, 79.7% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — OLMA ends flat (+0.0%) to $7.82
- Closed at $7.82, +0.00% vs the prior close of $7.82. Day range $7.72–$8.00, opened at $7.77.
- Volume was 758.20K shares, 0.7x its 50-day average of 1.09M.
- Price is -22.5% vs its 50-day average ($10.09) and -49.5% vs its 200-day average ($15.50).
- 52-week range $6.65–$36.26; today's close sits at 4% of that range, 78.4% below the 52-week high.
Oct 8, 2026 — OLMA dips 1.5% to $7.82, a 6-month low
- Closed at $7.82, -1.51% vs the prior close of $7.94. Day range $7.56–$8.21, opened at $7.87.
- Volume was 1.40M shares, 1.3x its 50-day average of 1.08M.
- Price is -23.1% vs its 50-day average ($10.17) and -49.9% vs its 200-day average ($15.60).
- 52-week range $6.65–$36.26; today's close sits at 4% of that range, 78.4% below the 52-week high.
Oct 7, 2026 — OLMA ends flat (+0.3%) to $7.94
- Closed at $7.94, +0.25% vs the prior close of $7.92. Day range $7.79–$8.23, opened at $7.90.
- Volume was 819.20K shares, 0.8x its 50-day average of 1.09M.
- Price is -22.4% vs its 50-day average ($10.24) and -49.4% vs its 200-day average ($15.70).
- 52-week range $6.65–$36.26; today's close sits at 4% of that range, 78.1% below the 52-week high.
Oct 6, 2026 — OLMA slides 4.0% to $7.92, a 6-month low
- Closed at $7.92, -4.00% vs the prior close of $8.25. Day range $7.80–$8.29, opened at $8.28.
- Volume was 1.04M shares, 1.0x its 50-day average of 1.09M.
- Price is -23.2% vs its 50-day average ($10.31) and -49.9% vs its 200-day average ($15.81).
- 52-week range $6.65–$36.26; today's close sits at 4% of that range, 78.2% below the 52-week high.
Oct 5, 2026 — OLMA rises 0.3% to $8.25
- Closed at $8.25, +0.30% vs the prior close of $8.23. Day range $7.85–$8.30, opened at $8.28.
- Volume was 1.01M shares, 0.9x its 50-day average of 1.08M.
- Price is -20.6% vs its 50-day average ($10.39) and -48.2% vs its 200-day average ($15.94).
- 52-week range $6.65–$36.26; today's close sits at 5% of that range, 77.2% below the 52-week high.
Oct 2, 2026 — OLMA dips 0.5% to $8.23, a 6-month low
- Closed at $8.23, -0.54% vs the prior close of $8.27. Day range $8.10–$8.52, opened at $8.39.
- Volume was 1.07M shares, 1.0x its 50-day average of 1.08M.
- Price is -21.4% vs its 50-day average ($10.46) and -48.8% vs its 200-day average ($16.07).
- 52-week range $6.65–$36.26; today's close sits at 5% of that range, 77.3% below the 52-week high.
OLMA latest news & SEC filings
Every SEC filing by or about OLMA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$63.20M (prior year -$43.78M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.61 (prior year -$0.51) (loss widened vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Harmon Cyrus sold 12,500 shares at $11.71 (≈$146.38K) on Jul 24, 2026
- Harmon Cyrus sold 12,500 shares at $11.71 (≈$146.38K) on Jul 24, 2026
- Harmon Cyrus sold 12,500 shares at $11.71 (≈$146.38K) on Jul 24, 2026
- Harmon Cyrus sold 12,500 shares at $11.71 (≈$146.38K) on Jul 24, 2026
- Harmon Cyrus sold 12,500 shares at $11.58 (≈$144.75K) on Jul 23, 2026
- Harmon Cyrus sold 12,500 shares at $11.58 (≈$144.75K) on Jul 23, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 24, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 23, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade OLMA
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 16, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.47% (largest 8.4%).
- Liquidity: about 1.24M shares (≈$8.17M) trade per day on average.
- 52-week position: $6.58 vs a range of $6.48–$36.26 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Cyrus Harmon sold 12,500 shares on Jul 24, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Aug 13, 2026; 10-Q Aug 10, 2026.
- Share count: 87.50M shares outstanding (Aug 6, 2026), +27.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
OLMA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 6.83 | 6.83 | 6.48 | 6.58 | 1.08M |
| Oct 15, 2026 | 6.84 | 6.95 | 6.70 | 6.87 | 1.09M |
| Oct 14, 2026 | 6.92 | 7.15 | 6.61 | 6.80 | 1.85M |
| Oct 13, 2026 | 7.30 | 7.36 | 6.99 | 7.02 | 2.01M |
| Oct 12, 2026 | 7.77 | 7.77 | 7.33 | 7.36 | 1.02M |
| Oct 9, 2026 | 7.77 | 8.00 | 7.72 | 7.82 | 758.20K |
| Oct 8, 2026 | 7.87 | 8.21 | 7.56 | 7.82 | 1.40M |
| Oct 7, 2026 | 7.90 | 8.23 | 7.79 | 7.94 | 819.20K |
| Oct 6, 2026 | 8.28 | 8.29 | 7.80 | 7.92 | 1.04M |
| Oct 5, 2026 | 8.28 | 8.30 | 7.85 | 8.25 | 1.01M |
| Oct 2, 2026 | 8.39 | 8.52 | 8.10 | 8.23 | 1.07M |
| Oct 1, 2026 | 8.58 | 8.66 | 8.19 | 8.27 | 1.01M |
| Sep 30, 2026 | 8.59 | 8.86 | 8.42 | 8.64 | 1.54M |
| Sep 29, 2026 | 8.60 | 8.73 | 8.46 | 8.54 | 1.08M |
| Sep 28, 2026 | 8.71 | 8.85 | 8.40 | 8.61 | 979.20K |
| Sep 25, 2026 | 9.04 | 9.04 | 8.57 | 8.75 | 1.38M |
| Sep 24, 2026 | 8.79 | 9.27 | 8.59 | 9.04 | 1.49M |
| Sep 23, 2026 | 9.64 | 9.64 | 8.70 | 8.83 | 1.64M |
| Sep 22, 2026 | 9.66 | 9.81 | 9.56 | 9.64 | 1.49M |
| Sep 21, 2026 | 9.95 | 10.13 | 9.61 | 9.63 | 1.07M |
About Olema Pharmaceuticals
Olema Pharmaceuticals (OLMA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1750284.
OLMA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Value Fund Ii Lp Biotechnology | See Explanation of Responses | Jun 23, 2026 |
| Value Fund L P Biotechnology | See Explanation of Responses | Jun 23, 2026 |
| Cynthia M Butitta | Director | Jun 23, 2026 |
| Gp Holdings Llc Bvf | See Explanation of Responses | Jun 23, 2026 |
| I Gp Llc Bvf | See Explanation of Responses | Jun 23, 2026 |
| Ii Gp Llc Bvf | See Explanation of Responses | Jun 23, 2026 |
| Inc/Il Bvf | See Explanation of Responses | Jun 23, 2026 |
| Partners L P/Il Bvf | See Explanation of Responses | Jun 23, 2026 |
| Partners Os Ltd. Bvf | See Explanation of Responses | Jun 23, 2026 |
| Value Trading Fund Os Lp Biotechnology | See Explanation of Responses | Jun 23, 2026 |
| Sean Bohen | PRESIDENT AND CEO | Feb 4, 2026 |
| Ian T Clark | Director | Jun 23, 2026 |
| J. Scott Garland | Director | Jun 23, 2026 |
| G. Walmsley Graham | Director | Jun 23, 2026 |
| Cyrus Harmon | Director | Jul 27, 2026 |
| Sandra Horning | Director | Jun 23, 2026 |
| Gorjan Hrustanovic | Director | Jun 23, 2026 |
| Mark N Lampert | See Explanation of Responses | Jun 23, 2026 |
| Yi Larson | Director | Jun 23, 2026 |
| Andrew Rappaport | Director | Jun 23, 2026 |
| Prakash Raman | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sasha Lu Austin | VP of Finance and Controller | Feb 17, 2026 |
| Sean Bohen | PRESIDENT AND CEO | Feb 4, 2026 |
| Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | Jan 15, 2026 |
| Shawnte Mitchell | CHIEF LEGAL OFFICER | Mar 5, 2026 |
| David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | Feb 4, 2026 |
| Jason O'Byrne | CHIEF FINANCIAL OFFICER | Sep 2, 2026 |
| Naseem Zojwalla | CHIEF MEDICAL OFFICER | Feb 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmon | Sale | 12,500 | $11.71 |
| Jul 24, 2026 | Cyrus Harmon | Sale | 12,500 | $11.71 |
| Jul 24, 2026 | Cyrus Harmon | Sale | 12,500 | $11.71 |
| Jul 24, 2026 | Cyrus Harmon | Sale | 12,500 | $11.71 |
| Jul 23, 2026 | Cyrus Harmon | Sale | 12,500 | $11.58 |
| Jul 23, 2026 | Cyrus Harmon | Sale | 12,500 | $11.58 |
| Jul 23, 2026 | Cyrus Harmon | Sale | 12,500 | $11.58 |
| Jul 23, 2026 | Cyrus Harmon | Sale | 12,500 | $11.58 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 233 | $24.69 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 24,767 | $24.25 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 233 | $24.69 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 24,767 | $24.25 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 233 | $24.69 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 24,767 | $24.25 |
| Mar 4, 2026 | Shawnte Mitchell | Sale | 233 | $24.69 |
OLMA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-162.45M | -1.87 | $-146.72M |
| Dec 31, 2024 | — | $-129.47M | -2.20 | $-104.35M |
| Dec 31, 2023 | — | $-96.66M | -2.14 | $-83.73M |
| Dec 31, 2022 | — | $-104.79M | -2.62 | $-82.06M |
| Dec 31, 2021 | — | $-71.10M | -1.80 | $-50.69M |
Latest balance sheet: total assets $486.58M, total liabilities $56.01M, cash $48.60M (as of Jun 30, 2026).
OLMA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $11.94 |
| May 12, 2026 | 8-K Item 2.02 (results) | $13.97 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $16.60 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $28.79 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $8.70 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $4.57 |
| May 13, 2025 | 8-K Item 2.02 (results) | $4.68 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $4.14 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $11.54 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on OLMA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.